CARA stock icon

Cara Therapeutics
CARA

$0.25
3.05%
 

About: Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Employees: 55

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 9 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,050% more call options, than puts

Call options by funds: $46K | Put options by funds: $4K

20% more capital invested

Capital invested by funds: $18.1M [Q4 2023] → $21.7M (+$3.57M) [Q1 2024]

1.58% less ownership

Funds ownership: 44.78% [Q4 2023] → 43.2% (-1.58%) [Q1 2024]

13% less funds holding

Funds holding: 112 [Q4 2023] → 97 (-15) [Q1 2024]

30% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 33

60% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 25

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$1
306%
upside
Avg. target
$4.96
1,910%
upside
High target
$10
3,955%
upside

9 analyst ratings

positive
89%
neutral
11%
negative
0%
Canaccord Genuity
Sumant Kulkarni
306%upside
$1
Hold
Downgraded
13 Jun 2024
Needham
Joseph Stringer
1,928%upside
$5
Buy
Reiterated
23 May 2024
HC Wainwright & Co.
Oren Livnat
1,360%upside
$3.6
Buy
Reiterated
15 May 2024
Needham
Joseph Stringer
1,928%upside
$5
Buy
Reiterated
14 May 2024
Needham
Joseph Stringer
1,928%upside
$5
Buy
Reiterated
10 Apr 2024

Financial journalist opinion

Based on 4 articles about CARA published over the past 30 days